Recent animal studies and clinical trials using bioartificial liver devices have shown great promise for the treatment for acute liver failure, and are providing valuable information on the problems and limitations of current ''1st generation"""""""" liver assist devices. It is becoming clearer every day, however, that more basic information of the effect of environmental parameters on hepatocellular function, as well as host-bioartificial liver interactions, is necessary before the concept of bioartificial liver becomes a reality available at reasonable cost. Our long-term objective is to help development of 2nd and 3rd generation devices, which are expected to be significantly more effective than currently available devices. In order to reach this goal, we require a better understanding of many critically important questions including: What is the minimum cell mass to support a patient? How long and well do hepatocytes function during plasma exposure? What are the most critical functions for patient survival? What is the impact of bioartificial liver treatment on the immune system and on subsequent liver transplantation? Answers to these questions will often not be obtainable using off-the-shelf tools, and will require the development of new experimental systems. Our main hypothesis is that there is a finite number of hepatic functions which are most critical for patient survival, that it is possible to significantly upregulate them in hepatocyte cultures (both at the single cell level and at the level of tissue), and as a result, reduce the cell mass required in the bioartificial liver.
The specific aims are: (1) To use metabolic and genetic engineering approaches to enhance the performance of hepatocyte cultures in plasma; (2) To optimize the oxygenation and geometric configuration of hepatocyte co-cultures for plasma detoxification; (3) To investigate patient-bioartificial liver interactions and characterize the immunological response to extracorporeal perfusion with allo- and xenogeneic cells. These studies will provide the basic knowledge and technologies enabling us to develop the next generation of liver assist devices and speed up the translation of this promising modality to the bedside. The proposed studies will also provide basic tools useful in the development of other engineered tissues and organs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK043371-12
Application #
6947307
Study Section
Surgery and Bioengineering Study Section (SB)
Program Officer
Serrano, Jose
Project Start
1992-09-30
Project End
2007-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
12
Fiscal Year
2005
Total Cost
$396,604
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Milwid, Jack M; Elman, Jessica S; Li, Matthew et al. (2014) Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Mol Ther 22:999-1007
Nativ, Nir I; Chen, Alvin I; Yarmush, Gabriel et al. (2014) Automated image analysis method for detecting and quantifying macrovesicular steatosis in hematoxylin and eosin-stained histology images of human livers. Liver Transpl 20:228-36
Li, Matthew; Tilles, Arno W; Milwid, Jack M et al. (2012) Phenotypic and functional characterization of human bone marrow stromal cells in hollow-fibre bioreactors. J Tissue Eng Regen Med 6:369-77
Jiao, Joy; Milwid, Jack M; Yarmush, Martin L et al. (2011) A mesenchymal stem cell potency assay. Methods Mol Biol 677:221-31
Cho, Cheul H; Park, Jaesung; Tilles, Arno W et al. (2010) Layered patterning of hepatocytes in co-culture systems using microfabricated stencils. Biotechniques 48:47-52
Roach, Kenneth L; King, Kevin R; Uygun, Korkut et al. (2009) High-throughput single cell arrays as a novel tool in biopreservation. Cryobiology 58:315-21
Yagi, Hiroshi; Parekkadan, Biju; Suganuma, Kazuhiro et al. (2009) Long-term superior performance of a stem cell/hepatocyte device for the treatment of acute liver failure. Tissue Eng Part A 15:3377-88
Berthiaume, François; Barbe, Laurent; Mokuno, Yasuji et al. (2009) Steatosis reversibly increases hepatocyte sensitivity to hypoxia-reoxygenation injury. J Surg Res 152:54-60
Sharma, Nripen S; Wallenstein, Eric J; Novik, Eric et al. (2009) Enrichment of hepatocyte-like cells with upregulated metabolic and differentiated function derived from embryonic stem cells using S-NitrosoAcetylPenicillamine. Tissue Eng Part C Methods 15:297-306
Nagrath, Deepak; Xu, Hongzhi; Tanimura, Yoko et al. (2009) Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. Metab Eng 11:274-83

Showing the most recent 10 out of 61 publications